Insmed (INSM) reported a Q1 net loss Thursday of $1.42 per diluted share, widening from a loss of $1.06 a year earlier.
Analysts polled by FactSet expected a loss of $1.34.
ARIKAYCE product revenue for the quarter ended March 31 was $92.8 million, up from $75.5 million a year earlier. ARIKAYCE is an inhaled antibiotic.
Analysts surveyed by FactSet expected $91.5 million.
For 2025, the biotech company continues to expect global ARIKAYCE product revenue of $405 million to $425 million. Analysts polled by FactSet expect $468.4 million.
Shares of the company were down aroun 0.04% in recent Thursday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。